2005 - Tobacco Smoking: Harm Reduction Strategies

Despite some tangible results, characterised by a slow progressive decrease in the number of smokers, related to the gradual awareness of the population about the health effects of tobacco smoking, a large group of smokers cannot or do not want to give up tobacco smoking, and, eventually, one out of two lifelong smokers will die of smoking related illnesses.

The main goals of this Seminar are to describe what is known, unknown, knowable, and unknowable, and how any harm reduction policy could fit within "denormalisation" and the "mainstream" tobacco/nicotine control policy.

2005 - Tobacco Smoking: Harm Reduction Strategies

2024 - Sleep apnea and its consequences: from animal models to precision medicine

2023 - In Vitro Diagnostic (IVD) tests to combat antimicrobial resistance in community-acquired low-respiratory tract infections (CA-LRTI)

2019 - New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine

The role of nicotine in cigarette related morbidity

N. Benowitz (San Francisco, Ca, United States of America)

Slides

Accompanying documents

The role of the other components of cigarette smoke in cigarette related morbidity

F. Wiebel (Eching/Munchen, Germany)

Slides

Nicotine addiction in animals : mechanisms and models

D. Balfour (Dundee, United Kingdom)

Slides

Accompanying documents

Tobacco smoking as an addiction

K. Fagerström (Helsingborg, Sweden)

Slides

Accompanying documents

What is harm reduction? Principles and observations from outside tobacco smoking

L. Gruer (Glasgow, United Kingdom)

Slides

Accompanying documents

Less harmful cigarettes and new cigarette substitutes

D. Sweanor (Ottawa, Ontario, Canada)

Accompanying documents

Smokefree tobacco

J. Foulds (New Brunswick, Nj, United States of America)

Slides

Accompanying documents

Nicotine Replacement Therapy

J. Houezec (Rennes, France)

Slides

Accompanying documents

The concept of Recreational clean addictive nicotine

N. Gray (Lyon, France)

Slides

Accompanying documents

What is at stake? What are the possible gains and risks?

M. Laugesen (Auckland Region, New Zealand)

Slides

Accompanying documents

What regulatory framework is preferable for successful harm reduction?

F. Godfrey (Luxemburg, Luxemburg)

Slides

Proposals for future ; general discussion

Y. Martinet (Vandoeuvre-Les Nancy, France)

Slides

Accompanying documents

How can Marketing help?

G. Hastings (Stirling, United Kingdom)

Slides

Tobacco Smoking: Harm Reduction Strategies - An ERS Research Seminar

Ann McNeill, University College London

Accompanying documents

CDN Connection Issue

2005 - Tobacco Smoking: Harm Reduction Strategies

2005 - Tobacco Smoking: Harm Reduction Strategies

#{title}